☰

Jennifer A. Mertz, Ph.D. - Publications

Affiliations: 
2003 University of Texas at Austin, Austin, Texas, U.S.A. 
Area:
Molecular Biology, Cell Biology
Tree Info Similar researchers PubMed Report error

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Mertz JA, Blum KA, Younes A, Abramson JS, Maris MB, Flinn IW, Goy A, Borger DR, Cooper MR, Sims RJ. Abstract 3674: Pharmacodynamic assessment in whole blood for the BET bromodomain inhibitor CPI-0610 of target engagement in patients with progressive lymphoma Cancer Research. 78: 3674-3674. DOI: 10.1158/1538-7445.Am2018-3674  0.33
2017 Conery AR, Centore RC, Spillane KL, Follmer NE, Bommi-Reddy A, Hatton C, Bryant BM, Greninger P, Amzallag A, Benes CH, Mertz JA, Sims RJ. Abstract B19: Targeting dependencies within apoptotic pathways through inhibition of BET bromodomains Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-B19  0.408
2016 Siu KT, Ramachandran J, Yee AJ, Eda H, Santo L, Panaroni C, Mertz JA, Sims RJ, Cooper MR, Raje N. Preclinical activity of CPI-0610, a novel small molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia. PMID 27890933 DOI: 10.1038/Leu.2016.355  0.421
2016 Huang Y, Nahar S, Nakagawa A, Fernandez de Barrena MG, Mertz JA, Bryant BM, Adams CE, Mino-Kenudson M, Von Alt K, Chang K, Conery AR, Hatton C, Sims RJ, Fernandez-Zapico ME, Wang X, et al. Regulation of GLI underlies a role for BET bromodomains in pancreatic cancer growth and the tumor microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27169995 DOI: 10.1158/1078-0432.Ccr-15-2068  0.304
2016 Ghosh S, Taylor A, Chin M, Huang HR, Conery AR, Mertz JA, Salmeron A, Dakle PJ, Mele D, Cote A, Jayaram H, Setser JW, Poy F, Hatzivassiliou G, DeAlmeida-Nagata D, et al. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. The Journal of Biological Chemistry. PMID 27056325 DOI: 10.1074/Jbc.M115.708560  0.369
2016 Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Cote A, Leblanc Y, Nasveschuk CG, Bellon S, Bergeron L, Campbell R, Cantone N, Cooper MR, Cummings RT, Jayaram H, Joshi S, ... Mertz JA, et al. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. Journal of Medicinal Chemistry. PMID 26815195 DOI: 10.1021/Acs.Jmedchem.5B01882  0.348
2016 Conery AR, Centore RC, Spillane KL, Follmer NE, Bommi-Reddy A, Hatton C, Bryant BM, Greninger P, Amzallag A, Benes CH, Mertz JA, Sims RJ. Preclinical anticancer efficacy of BET bromodomain inhibitors is determined by the apoptotic response. Cancer Research. PMID 26759243 DOI: 10.1158/0008-5472.Can-15-1458  0.354
2016 Conery AR, Centore RC, Neiss A, Keller PJ, Joshi S, Spillane KL, Sandy P, Hatton C, Pardo E, Zawadzke L, Bommi-Reddy A, Gascoigne KE, Bryant BM, Mertz JA, Sims RJ. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife. 5. PMID 26731516 DOI: 10.7554/Elife.10483  0.398
2016 Siu KT, Ramachandran J, Yee AJ, Eda H, Santo L, O'Donnell EK, Panaroni C, Mertz J, Sims RJ, Cooper M, Raje N. Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma Blood. 128: 3320-3320. DOI: 10.1182/Blood.V128.22.3320.3320  0.41
2016 Keller PJ, Conery AR, Centore RC, Bommi-Reddy A, Gascoigne KE, Bryant BM, Mertz JA, Sims RJ. Abstract 4749: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma Cancer Research. 76: 4749-4749. DOI: 10.1158/1538-7445.Am2016-4749  0.405
2015 Siu KT, Eda H, Santo L, Ramachandran J, Koulnis M, Mertz J, Sims RJ, Cooper M, Raje NS. Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma Blood. 126: 4255-4255. DOI: 10.1182/Blood.V126.23.4255.4255  0.414
2015 Liss AS, Nahar S, Mertz JA, Bryant B, Sims RJ, Castillo CF, Lillemoe KD, Warshaw AL, Thayer SP. Abstract B107: BET proteins are key mediators of pancreatic cancer cell growth and its tumor microenvironment Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-B107  0.416
2014 Follmer N, Mertz J, Conery A, Bryant B, Hatton C, Centore R, Huang H, Spillane K, Sims R. Abstract 2327: Defining the determinants of sensitivity and resistance to BET bromodomain inhibition Cancer Research. 74: 2327-2327. DOI: 10.1158/1538-7445.Am2014-2327  0.411
2012 Sims R, Normant E, Sandy P, Mertz J, Bryant B, O'Meara M, Green M, Cooper M, Audia J. Development of BET Protein Bromodomain Inhibition for the Treatment of Hematologic Malignancies Blood. 120: 1331-1331. DOI: 10.1182/Blood.V120.21.1331.1331  0.425
2011 Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of the United States of America. 108: 16669-74. PMID 21949397 DOI: 10.1073/Pnas.1108190108  0.452
2011 Sandy P, Mertz J, Conery A, Bryant B, Biagini L, Balasubramanian S, Lora J, Sims R, Bergeron L. Abstract B179: Mechanism of antitumor activity of BET inhibitors in models of lymphomas and leukemia. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B179  0.431
2011 Dudley JP, Mertz JA, Bhadra S, Palmarini M, Kozak CA. Endogenous retroviruses and cancer Retroviruses and Insights Into Cancer. 119-162. DOI: 10.1007/978-0-387-09581-3_5  0.558
2010 Byun H, Halani N, Mertz JA, Ali AF, Lozano MM, Dudley JP. Retroviral Rem protein requires processing by signal peptidase and retrotranslocation for nuclear function. Proceedings of the National Academy of Sciences of the United States of America. 107: 12287-92. PMID 20566871 DOI: 10.1073/Pnas.1004303107  0.593
2009 Mertz JA, Chadee AB, Byun H, Russell R, Dudley JP. Mapping of the functional boundaries and secondary structure of the mouse mammary tumor virus Rem-responsive element. The Journal of Biological Chemistry. 284: 25642-52. PMID 19632991 DOI: 10.1074/Jbc.M109.012476  0.623
2009 Mertz JA, Lozano MM, Dudley JP. Rev and Rex proteins of human complex retroviruses function with the MMTV Rem-responsive element. Retrovirology. 6: 10. PMID 19192308 DOI: 10.1186/1742-4690-6-10  0.627
2007 Mertz JA, Kobayashi R, Dudley JP. ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. Journal of Virology. 81: 3503-13. PMID 17229714 DOI: 10.1128/Jvi.02253-06  0.601
2005 Mertz JA, Simper MS, Lozano MM, Payne SM, Dudley JP. Mouse mammary tumor virus encodes a self-regulatory RNA export protein and is a complex retrovirus. Journal of Virology. 79: 14737-47. PMID 16282474 DOI: 10.1128/Jvi.79.23.14737-14747.2005  0.635
2002 Dudley JP, Mertz JA, Rajan L, Lozano M, Broussard DR. What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas. Leukemia. 16: 1086-98. PMID 12040439 DOI: 10.1038/Sj.Leu.2402451  0.594
2002 Broussard DR, Mertz JA, Lozano M, Dudley JP. Selection for c-myc integration sites in polyclonal T-cell lymphomas. Journal of Virology. 76: 2087-99. PMID 11836386 DOI: 10.1128/Jvi.76.5.2087-2099.2002  0.621
2001 Mertz JA, Mustafa F, Meyers S, Dudley JP. Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1. Journal of Virology. 75: 2174-84. PMID 11160721 DOI: 10.1128/Jvi.75.5.2174-2184.2001  0.617
Show low-probability matches.